Zacks Investment Research downgraded shares of SPECTRUM PHARMA (SPPI) from OUTPERFORM to UNDERPERFORM on August 29, 2012, with a target price of $10.90.
Spectrum Pharmaceuticals, Inc. is opportunistically acquiring and advancing a diversified portfolio of oncology drug candidates that meet critical health challenges for which there are few other treatment options. Spectrum's expertise lies in identifying undervalued drugs with demonstrated safety and efficacy, and adding value through further clinical development and selection of the most viable and low-risk methods of commercialization. The company's pipeline includes promising early and late-stage drug candidates with unique formulations and mechanisms of action that address the needs of seriously ill patients, such as at-home chemotherapy and new treatment regimens for refractory disease.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on SPECTRUM PHARMA (SPPI),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment